| 0.7578 -0.06 (-7.35%) | 02-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.32 | 1-year : | 1.74 |
| Resists | First : | 1.13 | Second : | 1.49 |
| Pivot price | 0.68 |
|||
| Supports | First : | 0.54 | Second : | 0.45 |
| MAs | MA(5) : | 0.7 |
MA(20) : | 0.7  |
| MA(100) : | 1.08 |
MA(250) : | 1.51 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 23.2 |
D(3) : | 17.1 |
| RSI | RSI(14): 50.8 |
|||
| 52-week | High : | 2.91 | Low : | 0.54 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ APRE ] has closed below upper band by 23.0%. Bollinger Bands are 12.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.84 - 0.85 | 0.85 - 0.85 |
| Low: | 0.7 - 0.71 | 0.71 - 0.71 |
| Close: | 0.75 - 0.76 | 0.76 - 0.76 |
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
Fri, 20 Feb 2026
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Wed, 18 Feb 2026
Aprea Therapeutics Stock Rises After Company Reports Second Unconfirmed Case Of Tumor Reduction In Trial - Stocktwits
Wed, 18 Feb 2026
Aprea Therapeutics Advanced Cancer Trial Shows Promising Results, Stock Soars - Benzinga
Wed, 18 Feb 2026
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Mon, 16 Feb 2026
Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference - Bitget
Thu, 12 Feb 2026
Aprea Therapeutics Expands Global Patent Portfolio for WEE1 and ATR Programs, Securing Exclusivity Through 2045 - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 4.49e+006 (%) |
| Held by Institutions | 19.5 (%) |
| Shares Short | 35 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.38e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -168 % |
| Return on Assets (ttm) | 689.8 % |
| Return on Equity (ttm) | -42 % |
| Qtrly Rev. Growth | 488240 % |
| Gross Profit (p.s.) | -61.81 |
| Sales Per Share | -46.41 |
| EBITDA (p.s.) | -4.91304e+006 |
| Qtrly Earnings Growth | -2.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 0.66 |
| Dividend | 0 |
| Forward Dividend | 35950 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|